An IgG‐based bispecific antibody for improved dual targeting in PSMA‐positive cancer
Open Access
- 29 December 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in EMBO Molecular Medicine
- Vol. 13 (2), e11902
- https://doi.org/10.15252/emmm.201911902
Abstract
The prostate‐specific membrane antigen (PSMA) has been demonstrated in numerous studies to be expressed specifically on prostate carcinoma cells and on the neovasculature of several other cancer entities. However, the simultaneous expression of PSMA on both, tumor cells as well as tumor vessels remains unclear, even if such “dual” expression would constitute an important asset to facilitate sufficient influx of effector cells to a given tumor site. We report here on the generation of a PSMA antibody, termed 10B3, which exerts superior dual reactivity on sections of prostate carcinoma and squamous cell carcinoma of the lung. 10B3 was used for the construction of T‐cell recruiting bispecific PSMAxCD3 antibodies in Fab‐ and IgG‐based formats, designated Fabsc and IgGsc, respectively. In vitro, both molecules exhibited comparable activity. In contrast, only the larger IgGsc molecule induced complete and durable elimination of established tumors in humanized mice due to favorable pharmacokinetic properties. Upon treatment of three patients with metastasized prostate carcinoma with the IgGsc reagent, marked activation of T cells and rapid reduction of elevated PSA levels were observed.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (SA1360/9‐1, SA1360/7‐3)
- Wilhelm Sander-Stiftung (2007.115.3)
- Deutsche Krebshilfe (111828, 70112914)
This publication has 45 references indexed in Scilit:
- Antitumor activities of PSMA×CD3 diabodies by redirected T-cell lysis of prostate cancer cellsImmunotherapy, 2013
- Reactivity and Applications of New Amine Reactive Cross-Linkers for Mass Spectrometric Detection of Protein−Protein ComplexesAnalytical Chemistry, 2009
- Target-dependent T-cell Activation by Coligation With a PSMA×CD3 Diabody Induces Lysis of Prostate Cancer CellsJournal of Immunotherapy, 2009
- A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cellsCancer Immunology, Immunotherapy, 2007
- Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidaseProceedings of the National Academy of Sciences, 2005
- Differential binding to human FcγRIIa and FcγRIIb receptors by human IgG wildtype and mutant antibodiesMolecular Immunology, 2003
- Targeting Metastatic Prostate Cancer With Radiolabeled Monoclonal Antibody J591 to the Extracellular Domain of Prostate Specific Membrane AntigenJournal of Urology, 2003
- Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigenSeminars in Oncology, 2003
- Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.1999
- Design and production of novel tetravalent bispecific antibodiesNature Biotechnology, 1997